|
|
|
|
|
|
Free Newsletters
Archive
My eNewsletters
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Login
Become a Member
Discussion Forums
FAQ
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
Accumetrics, Inc.'s VerifyNow(R) P2Y12 Test Provides Physicians with Information to Assess a Patient's Response to Newly-Approved Prasugrel (Effient(R))
7/14/2009
July 14, 2009, San Diego, Calif. – With the recent FDA approval of the new P2Y12
inhibitor, prasugrel (Effient), Accumetrics, Inc. announces that its VerifyNow P2Y12 Test
is not only able to assess response to Plavix®, but also its newly approved competitor,
Effient. In obtaining a result from the VerifyNow System, physicians are provided
objective information to determine the response of an individual patient to their
antiplatelet therapy, regardless of the P2Y12 inhibitor that is prescribed.
“We are very excited with our product position and timing with the release of this
therapeutic alternative to Plavix,” said Timothy I. Still, President and CEO of
Accumetrics. “We feel the VerifyNow System can dramatically contribute to a
physician’s ability to enhance care for patients undergoing percutaneous coronary
intervention and receiving the antiplatelet therapy that follows. In having this alternative
therapy, physicians now can now utilize the results of the VerifyNow System to assist in
the selection of the therapy that best achieves the desired antiplatelet effect.”
Accumetrics’ VerifyNow P2Y12 Test is used to measure the level of P2Y12 receptor
blockade and has been in use globally to assess a patient’s response to both clopidogrel
and prasugrel in clinical trials as well as in clinical practice within the hospital and
physician office settings.
About Accumetrics (www.accumetrics.com)
Accumetrics is committed to advancing medical understanding of platelet function and
enhancing quality of care for patients receiving antiplatelet therapies by providing
industry-leading and widely accessible diagnostic tests for rapid platelet function
assessment.
Accumetrics’ VerifyNow System is the first rapid and easy to use platform for measuring
an individual’s response to multiple antiplatelet agents. Addressing every major
antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g.
prasugrel (Effient) and clopidogrel (Plavix)), and the GP IIb/IIIa inhibitors (e.g. ReoPro®
and Integrilin®), the VerifyNow System provides a valuable tool to help physicians make
informed treatment decisions.
The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc.
ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of
Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis. Effient
is a registered trademark of Lilly-Daiichi Sankyo.
|
|
|
|
|
|
|
|
|
|
|
|